TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Brief Summary: The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.


Options:
A: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran
B: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
C: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
D: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pulsed Short Wave in Females With Knee Osteoarthritis: A Multicenter, Randomized, Placebo-controlled Clinical Trial
Brief Summary: Study design: Randomized clinical trial. Objective: To evaluate the effect of PSW treatment in different doses and to compare to the control and placebo group.

Background: Several forms of conservative treatment have been the focus of many recent studies in knee osteoarthritis (OA). Among these techniques, the application of pulsed short wave has been widely used, but the optimal dose and application time still have not been well established.


Options:
A: Arm Label: High dose PSW groups; Type: EXPERIMENTAL; Interventions: Device: Pulsed short wave | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Pulsed short wave | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Pulsed short wave; Assigned to Arm(s): High dose PSW groups, Placebo
B: Arm Label: Hip school; Type: ACTIVE_COMPARATOR; Interventions: Other: Hip School | Arm Label: Hip School and Manual Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Hip School and Manual Treatment | Arm Label: Minimal control intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Minimal control intervention | Intervention Type: OTHER; Name: Hip School; Assigned to Arm(s): Hip school | Intervention Type: OTHER; Name: Hip School and Manual Treatment; Assigned to Arm(s): Hip School and Manual Treatment | Intervention Type: OTHER; Name: Minimal control intervention; Assigned to Arm(s): Minimal control intervention
C: Arm Label: HIPL Therapy™ group; Type: EXPERIMENTAL; Interventions: Device: High Intensity Physio Light Therapy (HIPL Therapy™), Behavioral: Education, Behavioral: Aerobic Exercise, Behavioral: Resistance Exercise | Arm Label: Placebo Control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Education, Behavioral: Aerobic Exercise, Behavioral: Resistance Exercise, Device: Placebo Physio Light Therapy (HIPL Therapy™) | Intervention Type: DEVICE; Name: High Intensity Physio Light Therapy (HIPL Therapy™); Assigned to Arm(s): HIPL Therapy™ group | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: BEHAVIORAL; Name: Resistance Exercise; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: DEVICE; Name: Placebo Physio Light Therapy (HIPL Therapy™); Assigned to Arm(s): Placebo Control group
D: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: application of kinesio taping | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Other: application of kinesio taping | Intervention Type: OTHER; Name: application of kinesio taping; Assigned to Arm(s): Placebo group, intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)
Brief Summary: Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.

The aim of this study is to improve TB diagnosis in HIV-infected children by developing a new diagnostic algorithm incorporating new tools available such as:

* interferon gamma release assays (IGRAs), as alternative to the tuberculin skin test
* alternative specimen collection methods such as string test (or Enterotest (R)), nasopharyngeal aspirates and stools samples, as alternatives to gastric aspirate
* the Xpert MTB/RIF assay


Options:
A: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
B: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing
C: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention
D: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)
Brief Summary: Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.

The aim of this study is to improve TB diagnosis in HIV-infected children by developing a new diagnostic algorithm incorporating new tools available such as:

* interferon gamma release assays (IGRAs), as alternative to the tuberculin skin test
* alternative specimen collection methods such as string test (or Enterotest (R)), nasopharyngeal aspirates and stools samples, as alternatives to gastric aspirate
* the Xpert MTB/RIF assay


Options:
A: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
B: Arm Label: 0.1 µg/0.1 mL C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U. Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: 2 T.U. Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg/0.1 mL C-Tb | Intervention Type: BIOLOGICAL; Name: 2 T.U. Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U. Tuberculin PPD RT 23 SSI
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
D: Arm Label: 0.1 µg C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tuberculin PPD RT 23 SSI | Arm Label: 0.1 µg C-Tb / 2 T.U Tuberculin PPD; Type: EXPERIMENTAL; Interventions: Biological: C-Tb / Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg C-Tb | Intervention Type: BIOLOGICAL; Name: Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb / Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 0.1 µg C-Tb / 2 T.U Tuberculin PPD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)
Brief Summary: Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.

The aim of this study is to improve TB diagnosis in HIV-infected children by developing a new diagnostic algorithm incorporating new tools available such as:

* interferon gamma release assays (IGRAs), as alternative to the tuberculin skin test
* alternative specimen collection methods such as string test (or Enterotest (R)), nasopharyngeal aspirates and stools samples, as alternatives to gastric aspirate
* the Xpert MTB/RIF assay


Options:
A: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
B: Arm Label: Community level screening; Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Arm Label: Community level screening: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Intervention Type: DIAGNOSTIC_TEST; Name: Screening at community level; Assigned to Arm(s): Community level screening: Arm 2, Community level screening; Arm 1
C: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)
Brief Summary: Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.

The aim of this study is to improve TB diagnosis in HIV-infected children by developing a new diagnostic algorithm incorporating new tools available such as:

* interferon gamma release assays (IGRAs), as alternative to the tuberculin skin test
* alternative specimen collection methods such as string test (or Enterotest (R)), nasopharyngeal aspirates and stools samples, as alternatives to gastric aspirate
* the Xpert MTB/RIF assay


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
B: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
C: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
D: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 11-week Randomized, Double-blind, Multi Center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects S With Pain Associated With Diabetic Peripheral Neuropathy.
Brief Summary: Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.

This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.


Options:
A: Arm Label: 300 mg/day pregabalin (Lyrica); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched with pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 300 mg/day pregabalin (Lyrica) | Intervention Type: DRUG; Name: Placebo matched with pregabalin; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
D: Arm Label: Pregablain CR tablet 82.5 to 660mg; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregablain CR tablet 82.5 to 660mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal: a Randomised Controlled Trial.
Brief Summary: Randomised, placebo-controlled trial of continuous positive airway pressure therapy (CPAP) versus Provent® and Placebo-Provent® to define the effects of Provent® on the severity of obstructive sleep apnea, daytime symptoms as well as on measures of cardiovascular risk.


Options:
A: Arm Label: Standard Duty Hour Schedule; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Flexible Duty Hour Schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Flexible Duty Hour Schedule | Intervention Type: BEHAVIORAL; Name: Flexible Duty Hour Schedule; Assigned to Arm(s): Flexible Duty Hour Schedule
B: Arm Label: Intervention cohort; Type: EXPERIMENTAL; Interventions: Other: SCS intervention schedule | Arm Label: Control cohort; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SCS intervention schedule; Assigned to Arm(s): Intervention cohort
C: Arm Label: Provent; Type: ACTIVE_COMPARATOR; Interventions: Device: Provent® | Arm Label: Placebo-Provent; Type: PLACEBO_COMPARATOR; Interventions: Device: Provent®, Device: Placebo-Provent® | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Provent®, Procedure: CPAP | Intervention Type: DEVICE; Name: Provent®; Assigned to Arm(s): CPAP, Placebo-Provent, Provent | Intervention Type: DEVICE; Name: Placebo-Provent®; Assigned to Arm(s): Placebo-Provent | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: constant CPAP devices | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: automatic CPAP devices | Intervention Type: DEVICE; Name: constant CPAP devices; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: automatic CPAP devices; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome
Brief Summary: The objective of the study was to generate the data necessary to determine the gabapentin exposure produced by 4 dose levels of GEn (600 mg, 1200 mg, 1800 mg, and 2400 mg) or placebo, and the corresponding relief of symptoms in subjects with Restless Legs Syndrome (RLS).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: XP13512 (GSK1838262); Type: EXPERIMENTAL; Interventions: Drug: XP13512 (GSK1838262) | Intervention Type: DRUG; Name: XP13512 (GSK1838262); Assigned to Arm(s): XP13512 (GSK1838262) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: XP13512 600MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 600MG | Arm Label: XP13512 1200MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 1200MG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: XP13512 600MG; Assigned to Arm(s): XP13512 600MG | Intervention Type: DRUG; Name: XP13512 1200MG; Assigned to Arm(s): XP13512 1200MG | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): Placebo
C: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
D: Arm Label: GEn (XP13512/GSK1838262) 600 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1800 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 2400 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GEn (XP13512/GSK1838262); Assigned to Arm(s): GEn (XP13512/GSK1838262) 1200 mg, GEn (XP13512/GSK1838262) 1800 mg, GEn (XP13512/GSK1838262) 2400 mg, GEn (XP13512/GSK1838262) 600 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biomarkers in Autism of Aripiprazole and Risperidone Treatment
Brief Summary: The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism. BAART involves 3 academic centers across South Carolina. Although the FDA has approved use of the antipsychotic drug risperidone for irritability associated with autistic disorder, a moderate response rate in pivotal clinical trials and concerns over tolerability and weight gain can force clinicians to select alternative drug treatments for which evidence-based support is sparse.


Options:
A: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Balovaptan (RO5285119) 10 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Arm Label: Balovaptan (RO5285119) 4 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO5285119; Assigned to Arm(s): Balovaptan (RO5285119) 10 mg/d equivalent, Balovaptan (RO5285119) 4 mg/d equivalent
C: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
D: Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biomarkers in Autism of Aripiprazole and Risperidone Treatment
Brief Summary: The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism. BAART involves 3 academic centers across South Carolina. Although the FDA has approved use of the antipsychotic drug risperidone for irritability associated with autistic disorder, a moderate response rate in pivotal clinical trials and concerns over tolerability and weight gain can force clinicians to select alternative drug treatments for which evidence-based support is sparse.


Options:
A: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
C: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B